TMCnet - World's Largest Communications and Technology Community



Forty Seven to Present at Upcoming Investor Conferences in February
[February 06, 2020]

Forty Seven to Present at Upcoming Investor Conferences in February

MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences:

  • Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY.
  • 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 11:30 a.m. ET in New York, NY.

A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of Forty Seven’s website at A replay of the webcasts will be available on Forty Seven’s website for 90 days following each presentation.

About Forty Seven, Inc.

Forty Seven, Inc. is a clinicalstage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Forty Seven’s lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia and non-Hodgkin’s lymphoma.

For more information please visit or contact

For journalist enquiries please contact Sarah Plumridge at or phone (312) 506-5218.

For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at or phone (212) 362-1200.

Primary Logo

[ Back To's Homepage ]

Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments:
Comments about this site:


© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy